Shows
Medication TalkCardiovascular Impact of Diabetes MedsListen in as our expert panel discusses which diabetes meds have cardiovascular (CV) benefits. We’ll review the evidence and discuss the pros and cons of SGLT2 inhibitors (dapagliflozin, empagliflozin, etc) and GLP-1 agonists (dulaglutide, semaglutide, etc) in patients with or at risk for CV disease.Special Guests:Lauren G. Pamulapati, PharmD, BCACPAssociate Professor, Ambulatory CareVirginia Commonwealth University School of PharmacyClinical Pharmacist, Hayes Willis Health Center/VCU HealthChristie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy PracticeDirector, PGY2 Ambulatory Care Residency ProgramMidwestern University College of Pharmacy, Downers Grove CampusClinical Pharmacist, Northwestern MedicineTRC Editorial Adv...2025-04-0136 min
The Huddle: Conversations with the Diabetes Care TeamHelping Clients/Patients Meet Targets with GLP-1 and GIP/GLP-1 Receptor Agonists with Christie SchumacherChristie Schumacher PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, joins The Huddle to talk through the use of GLP-1 and GIP/GLP-1 receptor agonists for your people with type 2 diabetes. You’ll learn what medications fall into the class of GLP-1 and GIP/GLP-1 receptor agonists, how they work and the benefits they can offer people with type 2 diabetes. These medications can be a useful tool in the therapeutic toolkit as highlighted in the recently updated ADA/EASD consensus statement, so this episode will offer practical considerations when initiating GLP-1 and GIP/GLP-1 receptor agonists in patients and managing pos...2022-11-1619 min
ProCE: The Pharmacy Practice PodcastGLP-1 Receptor Agonist Use in Patients With Type 2 DiabetesIn this episode, pharmacists Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM, and Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, discuss the use of GLP-1 receptor agonists in patients with type 2 diabetes and provide answers to commonly asked questions. Listen to their conversation about the differences between short-acting vs long-acting agents; the benefits of use in combination with other medications, such as SGLT2 inhibitors, DPP-4 inhibitors, and metformin; their benefits in heart failure; and their role in the updated consensus statement from the American Diabetes Association/European Association for the Study of Diabetes. Presenters:...2022-11-0422 min